Potency of CAR T-Cell Therapy Investigated in Relapsed/Refractory MCL
August 22nd 2018Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.
Expanded Scalp Cooling Approval Offers Patients More Choices
August 20th 2018An expanded indication for the Paxman Scalp Cooling System to include the prevention of chemotherapy-related alopecia in patients with solid tumors will increase the population eligible for the therapy dramatically and allow for more personalized treatment options.
Experts Delve Into 4 Phenotypes of Advanced Prostate Cancer
August 20th 2018A panel of experts during an OncLive PeerExchange® provided practical definitions for biochemical recurrent hormone-naïve nonmetastatic, metastatic hormone-naïve advancing, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer.
CMS Decision Helps Unlock the Potential of Next-Generation Testing
August 17th 2018Provisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence the coverage thinking of commercial payers.
New Recommendations Improve Accuracy of HER2 Status Designation
August 17th 2018The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.